Background Statins reduce cardiovascular risks but increase the risk of new-onset diabetes (NOD). The aim of this study is to determine what effect, if any, statins have on the risk of NOD events in a population-based case-control study. An evaluation of the relationship between age and statin-exposure on NOD risks was further examined in a female Asian population. Method In a nationwide case-controlled study, the authors assessed 1065 female NOD patients and 10650 controls with matching ages, genders and physician visit dates. The impact of statin-exposure on NOD was examined through multiple logistic regression models. Subgroup analysis for exploring the risk of NOD and statin-exposure in different age groups was performed. Results Statin-exposure was statistically significantly associated with increased new-onset diabetes risks using multivariate analysis. Interaction effect between age and statin-exposure on NOD risk was noted. For atorvastatin, the risk of cDDDs>60 was highest among the 55–64 year-olds (adjusted odds ratio [OR], 8.0; 95% confidence interval [CI], 2.57–24.90). For rosuvastatin, the risk of cDDDs>60 was highest among the 40–54 year-olds (adjusted OR, 14.8; 95% CI, 2.27–96.15). For simvastatin, the risk of cDDDs>60 was highest among the 55–64 year-olds (adjusted OR, 15.8; 95% CI, 5.77–43.26). For pravastatin, the risk of cDDDs>60 was highest among the 55–64 year-olds (adjusted OR, 14.0; 95% CI, 1.56–125.18). Conclusions This population-based study found that statin use is associated with an increased risk of NOD in women. The risk of statin-related NOD was more evident for women aged 40–64 years compared to women aged 65 or more, and was cumulative-dose dependent. The use of statins should always be determined by weighing the clinical benefits and potential risks for NOD, and the patients should be continuously monitored for adverse effects.
References
[1]
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.
[2]
Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.
[3]
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
[4]
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735–742.
[5]
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ (2012) Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. The Lancet 380: 565–571.
[6]
Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, et al. (2012) Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 60: 1231–1238.
[7]
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305: 2556–2564.
[8]
Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, et al. (2011) Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 57: 1535–1545.
[9]
Ma T, Tien L, Fang CL, Liou YS, Jong GP (2012) Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther 34: 1977–1983.
[10]
Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, et al. (2012) Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 63: 358–366.
[11]
Ma T, Chang MH, Tien L, Liou YS, Jong GP (2012) The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging 29: 45–51.
[12]
Walsh JM, Pignone M (2004) Drug treatment of hyperlipidemia in women. JAMA 291: 2243–2252.
[13]
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, et al. (2012) Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 172: 144–152.
[14]
Abramson J, Wright JM (2007) Are lipid-lowering guidelines evidence-based? Lancet 369: 168–169.
[15]
Lin CC LM, Syu CY, Chang SC, Tseng FY (2005) Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 104: 157–163.
[16]
Chou FHC, Tsai KY, Su CY, Lee CC (2011) The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study. Schizophrenia research 129: 97–103.
[17]
Lee CC, Su YC, Ho HC, Hung SK, Lee MS, et al. (2011) Risk of Stroke in Patients Hospitalized for Isolated Vertigo. Stroke 42: 48–52.
[18]
Chang CM, Huang KY, Hsu TW, Su YC, Yang WZ, et al. (2012) Multivariate Analyses to Assess the Effects of Surgeon and Hospital Volume on Cancer Survival Rates: A Nationwide Population-Based Study in Taiwan. PLoS ONE 7: e40590.
[19]
Shah RV, Goldfine AB (2012) Statins and risk of new-onset diabetes mellitus. Circulation 126: e282–284.
[20]
Ma Y, Culver A, Rossouw J, Olendzki B, Merriam P, et al. (2013) Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? Ther Adv Cardiovasc Dis 7: 41–44.
[21]
Weng C, Yuan H, Tang X, Huang Z, Yang K, et al. (2012) Age- and gender dependent association between components of metabolic syndrome and subclinical arterial stiffness in a Chinese population. Int J Med Sci 9: 730–737.
[22]
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, et al.. (2013) Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. Am J Cardiol.
[23]
Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357–362.
[24]
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, et al. (2009) Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204: 483–490.
[25]
Mita T, Watada H, Nakayama S, Abe M, Ogihara T, et al. (2007) Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 54: 441–447.
[26]
Koh KK, Sakuma I, Quon MJ (2011) Differential metabolic effects of distinct statins. Atherosclerosis 215: 1–8.
[27]
Baker WL, Talati R, White CM, Coleman CI (2010) Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 87: 98–107.
[28]
Abbas A, Milles J, Ramachandran S (2012) Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia. Clin Med Insights Endocrinol Diabetes 5: 13–30.
[29]
Xia F, Xie L, Mihic A, Gao X, Chen Y, et al. (2008) Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 149: 5136–5145.
